Tests magnetic stimulation to ease movement symptoms in Parkinson's disease
Tests magnetic brain stimulation against placebo in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: The Efficacy and Safety of Precision REpetitive Transcranial Magnetic Stimulation in Alleviating Motor Symptom in Parkinson's Disease
Key facts
- Where
- Hefei, ChinaSee the site
Where in China
- Cognitive Neuropsychology Lab Anhui Medical UniversityHefei, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Anhui Medical University
- Trial code
- NCT06383247
- Record updated
- 17 June 2025
- Original description
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.Read full original descriptionShow less
A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive and widely used neuromodulation technology. Small sample studies have shown that rTMS treatment can significantly improve the symptoms of Parkinson's disease(PD) and delay the progression of the disease. In order to further explore the effectiveness of rTMS in the treatment of PD and lay the foundation for its clinical promotion, our research team plans to conduct a randomized double-blind controlled study of rTMS in the treatment of PD in multiple centers across the country.
Inclusion: Age ≥ 40 years old; Meet the diagnostic criteria for idiopathic Parkinson's disease (MDS Diagnostic Criteria for Parkinson's Disease (2015 Edition))[1]; Have no history of drug adjustment within 4 weeks before treatment and the entire study period; The MDS-UPDRS Ⅲ score ≥8, and the Hoehn-Yahr rating is 1-4; MMSE ≥22，able to cooperate with the completion of behavioral tests and transcranial magnetic stimulation therapy.
Exclusion: Previously head MRI/CT was focal brain injury or severe leukoencephalopathy (Fazekas grade 3 and above); Severe craniocerebral trauma, received craniocerebral surgery or deep brain stimulation treatment; Participants in any clinical trial within the previous 6 month; Various secondary parkinsonism syndromes (vascular parkinsonism, Parkinsonism combined with parkinsonism, drug parkinsonism, etc.); There are ferromagnetic implants in the body, such as cochlear implants, cardiac pacemakers, etc; The person has a history of epilepsy, unexplained loss of consciousness, or are taking anticonvulsant drugs to treat epileptic seizures; Diagnosed with a neuropsychiatric disorder other than PD; Have a history of drug abuse or drug use; Other conditions deemed unsuitable for inclusion by the investigator; Pregnant/lactating women or subjects (including men) who have a birth plan within 6 months.